TB
Elite in Metastatic Brain Tumor

Dr. Tracy T. Batchelor

Brigham And Women's Hospital, Neurosciences Center
Boston, MA
Elite
 in Metastatic Brain Tumor
Specialties:Neurology
Experience:33 Years
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Tracy T. Batchelor's experience treating your condition:
About Dr. Tracy T. Batchelor

Tracy Batchelor is a Neurologist in Boston, Massachusetts. Batchelor has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Tissue Biopsy, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts. Batchelor is currently accepting new patients.

His clinical research consists of co-authoring 254 peer reviewed articles and participating in 16 clinical trials in the past 15 years. In particular, he has co-authored 17 articles in the study of Metastatic Brain Tumor.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Tracy T. Batchelor it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
60 Fenwood Rd, 1st Floor, Boston, MA 02115
Other Locations
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Emory University School Of Medicine, 1990
Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Milford Regional Medical Center
Brigham And Womens Hospital
Massachusetts General Hospital
Dana Farber Cancer Institute
Beth Israel Deaconess Hospital - Plymouth
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Enrollment Status: Recruiting
Publish Date: August 25, 2022
Intervention Type: Biological
Study Drug: SurVaxM
Study Phase: Phase 2
Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Other, Radiation, Drug
Study Drugs: CediranibTemozolomide
Study Phase: Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: August 17, 2021
Intervention Type: Drug, Procedure
Study Drugs: CarmustineCytarabineEtoposideThiotepaGranulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using FMISO PET and Vascular MRI
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Device
Study Phase: Not Applicable
An Open-Label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)
Enrollment Status: Completed
Publish Date: August 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs
Enrollment Status: Completed
Publish Date: September 21, 2017
Intervention Type: Procedure, Other, Radiation, Drug
Study Phase: Phase 1/Phase 2
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: April 07, 2017
Intervention Type: Drug, Other, Procedure
Study Phase: Phase 1/Phase 2
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
Enrollment Status: Completed
Publish Date: December 28, 2016
Intervention Type: Drug
Study Phase: Phase 3
An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
Enrollment Status: Completed
Publish Date: July 25, 2016
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 01, 2015
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: October 21, 2013
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase II Study of AZD2171 in Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: August 22, 2013
Intervention Type: Drug
Study Phase: Phase 2
Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults With Newly Diagnosed Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: January 24, 2013
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy
Enrollment Status: Completed
Publish Date: November 25, 2009
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials -
254 Total Publications
Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
Journal: Neuro-oncology advances
Published: September 08, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
EU
Dr. Erik J. Uhlmann
Neurology
Elite
Highly rated in
24
conditions
Neurology

Beth Israel Lahey Health

Beth Israel Deaconess Medical Center

330 Brookline Ave, 
Boston, MA 
 0.4 mi

Erik Uhlmann is a Neurologist in Boston, Massachusetts. Uhlmann has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Metastatic Brain Tumor, Brain Tumor, Glioblastoma, Glioma, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts and Missouri. Uhlmann is currently accepting new patients.

PW
Dr. Patrick Y. Wen
Neurology
Elite
Highly rated in
26
conditions
Neurology

Dana Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 0.2 mi

Patrick Wen is a Neurologist in Boston, Massachusetts. Wen has been practicing medicine for over 42 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Gamma Knife Radiosurgery. He is licensed to treat patients in Massachusetts. Wen is currently accepting new patients.

EG
Dr. Elizabeth R. Gerstner
Neurology
Elite
Highly rated in
18
conditions
Neurology

Mass General Brigham

Pappas Center For Neuro Oncology

55 Fruit St, 
Boston, MA 
 2.8 mi

Elizabeth Gerstner is a Neurologist in Boston, Massachusetts. Gerstner has been practicing medicine for over 21 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 18 other conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Awake Craniotomy. She is licensed to treat patients in Massachusetts. Gerstner is currently accepting new patients.